No­var­tis’ $2B can­cer drug spurs ‘ground­break­ing’ PhI­II da­ta for prostate can­cer

Con­tin­u­ing a streak of up­beat an­nounce­ments on its ra­di­oli­gand port­fo­lio, No­var­tis says that their Phase III study of 177Lu-PS­MA-617 hit both co-pri­ma­ry end­points on over­all sur­vival and ra­di­ograph­ic pro­gres­sion-free sur­vival for prostate can­cer pa­tients — set­ting up a like­ly ap­proval some an­a­lysts be­lieve would be worth more than a bil­lion dol­lars a year in peak sales.

In­ves­ti­ga­tors tried the treat­ment on pro­gres­sive PS­MA-pos­i­tive metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer pa­tients, com­par­ing it against stan­dard of care. We don’t have the ex­act da­ta, but No­var­tis typ­i­cal­ly holds back spe­cif­ic re­sults for the can­cer con­fer­ences.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.